Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema
Psoriasis is a chronic inflammatory disease which mostly affects skin. Tildrakizumab is a specific anti‐interleukin‐23p19 monoclonal antibody approved for the treatment of plaque psoriasis in adults. Herein, we report about a patient who came to our attention for a moderate-to-severe plaque psorias...
Main Authors: | Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2022-10-01
|
Series: | Dermatology Reports |
Subjects: | |
Online Access: | https://www.pagepress.org/journals/index.php/dr/article/view/9447 |
Similar Items
-
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
by: Boni Elewski, et al.
Published: (2020-11-01) -
Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01) -
A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
by: Thomas Damsin
Published: (2023-06-01) -
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
by: Steven R. Feldman, et al.
Published: (2022-04-01) -
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
by: Xiaoying Jia, et al.
Published: (2022-02-01)